Welcome to our dedicated page for National Resh news (Ticker: NRC), a resource for investors and traders seeking the latest updates and insights on National Resh stock.
NRC Health (National Research Corporation, NASDAQ: NRC) generates a steady stream of news focused on healthcare experience management, financial performance, and partnerships with health systems. This news page aggregates updates from company press releases, third-party announcements, and regulatory disclosures so readers can follow how NRC Health is working with healthcare organizations and how its business is evolving over time.
Many NRC Health news items highlight new and expanded partnerships with hospitals and health systems. Recent examples include collaborations with Mosaic Life Care, BJC Health System, North Mississippi Health Services, and South Shore Health. These announcements describe how NRC Health’s patient experience, employee experience, and market insight capabilities are being used to support human-centered care, unify feedback, and guide improvement across hospitals, clinics, and other care settings.
Investors and industry observers will also find coverage of NRC Health’s quarterly results, including revenue trends, Total Recurring Contract Value (TRCV), cash flow from operations, and non-GAAP measures such as Adjusted EBITDA and Adjusted Net Income. These earnings releases often include commentary from company leadership about sales activity, customer retention, and capital allocation through dividends and share repurchases.
Additional news includes leadership appointments, such as executive roles in finance and strategic insights, and recognition related to healthcare experience management, including references to the Best in KLAS Award for Healthcare Experience Management and Excellence in Patient Experience awards given by NRC Health to client organizations. Readers who want to monitor NRC Health’s role in healthcare experience improvement, its relationships with health systems, and its public company disclosures can use this page as a centralized source of updates.
On August 2, 2022, National Research Corporation (NASDAQ:NRC) reported a 2% increase in Q2 2022 revenue, totaling $37.3 million, compared to $36.4 million in Q2 2021. However, operating income fell by 6% to $11.5 million, with net income decreasing to $8.3 million from $8.9 million. Diluted earnings per share also declined to $0.33. The company secured its first contract for the Human Understanding Program with Novant Health and continues to prioritize organic growth, despite challenges from discontinued offerings impacting revenue growth.
National Research Corporation (NASDAQ:NRC) will host a web simulcast of its Q2 2022 earnings conference call on August 3, 2022, following the market close on August 2, 2022, when the earnings results will be released. The live broadcast starts at 11:00 a.m. ET and will be available for replay for 30 days. NRC has over 40 years of experience in enhancing healthcare through Human Understanding, helping organizations improve customer experiences and trust.
Summary not available.
NRC Health announced a quarterly cash dividend of $0.24 per share payable on July 15, 2022, to shareholders on record by June 30, 2022. Additionally, the Board of Directors approved a new stock repurchase authorization of up to 2.5 million shares. This buyback will occur based on market conditions and corporate considerations. The previous repurchase authorization has concluded, and the new one has no expiration date, reflecting NRC Health's commitment to enhancing shareholder value.
NRC Health has appointed Parul Bhandari, a Microsoft executive, to its Board of Directors as of May 19, 2022. Bhandari brings over 20 years of experience in technology and digital transformation, focusing on leveraging data and AI for healthcare improvement. Her role will enhance NRC's mission to foster Human Understanding in healthcare. With a solid background in business development and strategy, Bhandari aims to address the challenges of balancing technology with human-centric care delivery.
National Research Corporation (NASDAQ:NRC) reported an 8% revenue increase in Q1 2022, reaching $38.4 million compared to $35.5 million in Q1 2021. However, operating income fell by 3% to $11.7 million, and net income decreased to $8.5 million from $9.2 million year-over-year. Diluted earnings per share dropped to $0.34, down from $0.36. The company is focused on organic growth, enhancing core offerings like the Human Understanding Program, while also investing in innovation and employee benefits. Cash flow from operations decreased to $8.3 million, but net cash rose to $21.8 million.
NRC Health (NASDAQ:NRC) will host a first quarter earnings conference call on May 4, 2022, following the release of financial results after market close on May 3, 2022. The conference call will start at 11:00 a.m. ET and will be available via a live audio webcast. A replay will be accessible for 30 days after the event. NRC Health has been dedicated to enhancing human understanding in healthcare for over 40 years, focusing on improving key experiences that build trust between healthcare organizations and their clients.
NRC Health released its 2022 Pediatric Consumer Trends Report, highlighting the evolving needs of pediatric consumers post-COVID. Key findings indicate a 135% increase in parents resuming healthcare services since 2020, a 5.2% rise in telehealth adoption, and a 163% surge in mental health hospitalizations among youth. Despite these trends, pediatric marketing recall remains stagnant at 1.5%, and the Net Promoter Score for pediatric services has declined from 69 in April 2020 to 53 in December 2021. The report underscores the importance of addressing these challenges in pediatric healthcare.
NRC Health announced a quarterly cash dividend of $0.24 per share, payable on April 15, 2022. Shareholders of record as of March 31, 2022 will receive this dividend. NRC Health, a leader in analytics and insights for over 40 years, focuses on measurement and enhancement of Human Understanding.
National Research Corporation (NASDAQ:NRC) reported strong Q4 2021 results, with a 10% revenue increase to $38.3 million and a 26% operating income rise to $12.9 million, resulting in an operating margin of 34%. For the full year, revenue was $148.0 million (+11%) and operating income was $50.3 million (+18%). Diluted EPS increased to $0.38 in Q4 and $1.46 for the year. The launch of the Human Understanding Program aims to enhance personalized care across healthcare systems. The company's cash flow from operations grew to $46.3 million, boosting net cash to $27.8 million.